EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Anti‐TNF Therapy Is Associated With Browning‐ and Immune‐Related Changes in Creeping Fat in Crohn's Disease

Diandra Monfort-Ferré iD, Iris Ginés iD, Claudia Cepero, Laia Cabré iD, Aledis Caro, Margarita Menacho, Miriam Gené iD, Montserrat Garcia, Maria Del Carmen Lahoz, Maria José Mañas, Marc Martí iD, Aitana Tarzán iD und 4 weitere

United European Gastroenterology Journal · 2026-11 · 14 (9)

DOI: 10.1002/ueg2.70320 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 04.11.2026. Verfasst von Diandra Monfort-Ferré und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari de Tarragona Joan XXIII, Institut de Recerca Biomèdica Catalunya Sud (formerly Institut d'Investigació Sanitària Pere Virgili),…. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Tumor Necrosis Factor-alpha, Adipose Tissue, Brown. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, Ministerio de Ciencia, Innovación y Universidades.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Creeping fat (CrF) in Crohn's disease (CD) is a metabolically active perilesional adipose tissue involved in intestinal inflammation. Whether biological therapies modify its browning‐associated phenotype remains largely unexplored. We investigated whether anti‐TNF treatment is associated with changes in browning‐, mitochondrial biogenesis‐ and immune‐related pathways in CrF and whether similar molecular changes occur following ex vivo infliximab exposure.

Methods

Two independent human cohorts were analysed. (1) Observational cohort: CrF biopsies from anti‐TNF‐treated and anti‐TNF–naïve CD patients ( n = 14 and n = 19, respectively) were analysed for metabolic and inflammatory gene and protein expression. AdMSCs and mature CrF‐derived adipocytes were isolated, and UCP1 protein abundance was assessed by immunohistochemistry and western blotting. (2) Ex vivo cohort: Paired CrF explants from anti‐TNF‐naïve patients with CD undergoing surgery were cultured with or without infliximab (5 mg/kg‐equivalent, 24 h) and analysed by RT‐qPCR and immunohistochemistry.

Results

Anti‐TNF‐treated patients showed higher UCP1 expression in CrF at mRNA and protein levels. CrF‐derived mature adipocytes from treated patients exhibited increased expression of browning‐/thermogenesis‐ and mitochondrial biogenesis‐associated genes, together with reduced selected pro‐inflammatory markers. AdMSCs also showed exploratory differences in their conditioned‐medium protein profile, although no protein remained significant after FDR correction. Ex vivo infliximab exposure was associated with changes in selected browning‐, mitochondrial biogenesis‐ and immune‐related markers.

Discussion

Together, the observational and ex vivo findings identify CrF as an anti‐TNF‐responsive immunometabolic compartment in CD, characterised by coordinated browning‐, mitochondrial biogenesis‐ and immune‐related molecular changes. Functional studies are needed to establish the metabolic significance of these changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabTumor Necrosis Factor-alphaAdipose Tissue, BrownGastrointestinal AgentsHumansFemaleAdultMaleUncoupling Protein 1Middle AgedAdipocytesYoung AdultBiopsyCells, Cultured

Stichwörter der Autor:innen

adipose tissuebiologicsbrowninginflammatory bowel diseasesinfliximabmitochondrial biogenesis

Substanzen

InfliximabTumor Necrosis Factor-alphaUncoupling Protein 1UCP1 protein, humanGastrointestinal Agents

Autor:innen und Institutionen

  • Hospital Universitari de Tarragona Joan XXIII, Institut de Recerca Biomèdica Catalunya Sud (formerly Institut d'Investigació Sanitària Pere Virgili), Tarragona, Spain.
  • Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, Tarragona, Spain.
  • Department of Gastroenterology, Hospital Universitari de Tarragona Joan XXIII, Institut de Recerca Biomèdica Catalunya Sud, Tarragona, Spain.
  • Colorectal Surgery Unit, Hospital Universitari de Tarragona Joan XXIII, Institut de Recerca Biomèdica Catalunya Sud, Tarragona, Spain.
  • Department of Medicine and Surgery, Universitat Rovira i Virgili, Reus, Spain.
  • Department of Pathology, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.

ORCID-Profile: Diandra Monfort-Ferré, Iris Ginés, Laia Cabré, Miriam Gené, Marc Martí, Aitana Tarzán, Roger Suau, Joan Ferreres, Josep Manyé, Carolina Serena

Förderung

  • Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
  • Ministerio de Ciencia, Innovación y Universidades

Zitieren

APA

Monfort-Ferré, D., Ginés, I., Cepero, C., Cabré, L., Caro, A., Menacho, M., Gené, M., Garcia, M., Lahoz, M. D. C., Mañas, M. J., Martí, M., Tarzán, A., Suau, R., Ferreres, J., Manyé, J., & Serena, C. (2026). Anti‐TNF Therapy Is Associated With Browning‐ and Immune‐Related Changes in Creeping Fat in Crohn's Disease. United European Gastroenterology Journal, 14(9). https://doi.org/10.1002/ueg2.70320

Vancouver

Monfort-Ferré D, Ginés I, Cepero C, Cabré L, Caro A, Menacho M, et al. Anti‐TNF Therapy Is Associated With Browning‐ and Immune‐Related Changes in Creeping Fat in Crohn's Disease. United European Gastroenterology Journal. 2026;14(9). doi:10.1002/ueg2.70320

BibTeX
@article{MonfortFerr2026,
  author = {Monfort-Ferré, Diandra and Ginés, Iris and Cepero, Claudia and Cabré, Laia and Caro, Aledis and Menacho, Margarita and Gené, Miriam and Garcia, Montserrat and Lahoz, Maria Del Carmen and Mañas, Maria José and Martí, Marc and Tarzán, Aitana and Suau, Roger and Ferreres, Joan and Manyé, Josep and Serena, Carolina},
  title = {Anti‐TNF Therapy Is Associated With Browning‐ and Immune‐Related Changes in Creeping Fat in Crohn's Disease},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {9},
  doi = {10.1002/ueg2.70320}
}
Kostenlos starten →